Effective and evidence-based management strategies for rosacea: Summary of a Cochrane systematic review

British Journal of Dermatology

Volumn 165, Issue 4, 2011, Pages 760-781

  Van Zuuren, E J ^a   Kramer, S F ^b   Carter, B R ^c   Graber, M A ^d   Fedorowicz, Z ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF IOWA   (United States)

^e Ministry of Health   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ARTIFICIAL TEAR; AZELAIC ACID; AZITHROMYCIN; BENZOYL PEROXIDE; CLARITHROMYCIN; CLINDAMYCIN; CYCLOSPORIN A; DOXYCYCLINE; ERYTHROMYCIN; HYDROCORTISONE; METRONIDAZOLE; NADOLOL; OMEPRAZOLE; OXYTETRACYCLINE; PERMETHRIN; PIMECROLIMUS; RILMENIDINE; SULFACETAMIDE; SULFUR; TETRACYCLINE; ZINC SULFATE;

DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ROSACEA; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; ANTI-BACTERIAL AGENTS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSACEA; SELECTION BIAS; TREATMENT OUTCOME;

EID: 80053508629     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10473.x     Document Type: Review

References (71)

1. Crawford GH, Pelle MT, James WD,. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-41. (Pubitemid 39178655)
2. Korting HC, Schöllmann C,. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 2009; 23: 876-82.
3. Powell FC,. Clinical practice. Rosacea. N Engl J Med 2005; 352: 793-803.
4. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46: 584-7.
5. Wilkin J, Dahl M, Detmar M, et al. National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2004; 50: 907-12. (Pubitemid 38685771)
6. Pelle MT, Crawford GH, James WD,. Rosacea: II. Therapy. J Am Acad Dermatol 2004; 51: 499-512.
7. Baldwin HE,. Oral therapy for rosacea. J Drugs Dermatol 2006; 5: 16-21.
8. Jansen T, Plewig G,. Rosacea: classification and treatment. J R Soc Med 1997; 90: 144-50. (Pubitemid 27135946)
9. Bikowski JB, Goldman MP,. Rosacea: where are we now? J Drugs Dermatol 2004; 3: 251-61.
10. Elewski BE, Draelos Z, Dréno B, et al. Rosacea-global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25: 188-200.
11. van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev 2011; 3: CD003262.
12. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available from, 2011.
13. Treadwell JT, Tregear SJ, Reston JT, et al. A system for rating the stability and strength of medical evidence. BMC Med Res Methodol 2006; 6: 52.
14. Barnhorst DA, Foster JA, Chern KC, et al. The efficacy of topical metronidazole in the treatment of ocular rosacea. Ophthalmology 1996; 103: 1880-3. (Pubitemid 26403743)
15. Schechter BA, Katz RS, Friedman LS,. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther 2009; 26: 651-9.
16. Weissenbacher S, Merkl J, Hildebrandt B, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol 2007; 156: 728-32. (Pubitemid 46452339)
17. Bleicher PA, Charles JH, Sober AJ,. Topical metronidazole therapy for rosacea. Arch Dermatol 1987; 123: 609-14. (Pubitemid 17069507)
18. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802. (Pubitemid 46561002)
19. Beutner K, Calvarese B,. A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. J Am Acad Dermatol 2005; 52 (Suppl. 3): P10.
20. Bitar A, Bourgouin J, Doré N, et al. A double-blind randomized study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea, a placebo controlled study. Drug Invest 1990; 2: 242-8.
21. Bjerke JR, Nyfors A, Austad J, et al. Metronidazole (Elyzol) 1% cream vs. placebo cream in the treatment of rosacea. Clin Trials J 1989; 26: 187-94. (Pubitemid 19151205)
22. Breneman DL, Stewart D, Hevia O, et al. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis 1998; 61: 44-7. (Pubitemid 128471937)
23. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol 1998; 134: 679-83. (Pubitemid 28283718)
24. Dahl MV, Jarratt MJ, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of papules and pustules of rosacea. J Am Acad Dermatol 2001; 45: 723-30. (Pubitemid 33032570)
25. Dreno B, Dubertret L, Naeyaert JM, et al. Comparison of the clinical efficacy and safety of metronidazole 0·75% cream with metronidazole 0·75% gel in the treatment of rosacea. J Eur Acad Dermatol Venereol 1998; 11 (Suppl. 2): S272-3.
26. Guillet B, Rostain E, Powell F, et al. Metronidazole 0·75% gel and lotion are both effective in the treatment of rosacea. J Eur Acad Dermatol Venereol 1999; 12 (Suppl. 2): S145.
27. Jorizzo JL, Lebwohl M, Tobey RE,. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double blind clinical trial. J Am Acad Dermatol 1998; 39: 502-4. (Pubitemid 28417396)
28. Koçak M, Yagli S, Vahapoglu G, et al. Permethrin 5% cream versus metronidazole 0·75% gel for the treatment of papulopustular rosacea. Dermatology 2002; 205: 265-70. (Pubitemid 36158538)
29. Nielsen PG,. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br J Dermatol 1983; 108: 327-32.
30. Tan JKL, Girard C, Krol A, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea. J Cutan Med Surg 2002; 6: 529-34. (Pubitemid 36091497)
31. Bjerke R, Fyrand O, Graupe K,. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venerol 1999; 79: 456-9.
32. Carmichael AJ, Marks R, Graupe KA, et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4 (Suppl. 1): S19-22. (Pubitemid 23216497)
33. Thiboutot D, Thieroff-Ekerdt R, Graupe K,. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from 2 vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-45. (Pubitemid 36706214)
34. Thiboutot DM, Fleisher AB, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol 2008; 7: 541-6.
35. Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy. J Drugs Dermatol 2009; 8: 639-48.
36. Elewski BE, Fleisher AB, Pariser DM,. A comparison of 15% azelaic acid gel and 0·75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol 2003; 139: 1444-50. (Pubitemid 37433134)
37. Maddin S,. A comparison of topical azelaic acid 20% cream and topical metronidazole 0·75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40 (6 Pt 1): 961-5. (Pubitemid 29268928)
38. Wolf JE Jr, Kerrouche N, Arsonnaud S,. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis 2006; 77 (Suppl. 4): 3-11. (Pubitemid 43723532)
39. Breneman D, Savin R, VandePol C, et al. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of moderate to severe rosacea. Int J Dermatol 2004; 43: 381-7. (Pubitemid 38714606)
40. Draelos ZD, Fuller BB,. Efficacy of 1% 4-ethoxybenzaldehyde in reducing facial erythema. Dermatol Surg 2005; 31 (7 Pt 2): 881-5.
41. Draelos ZD, Green BA, Edison BL,. An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. J Cosmet Dermatol 2006; 5: 23-9.
42. Koca R, Altinyazar HC, Ankarali H, et al. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial. Clin Exp Dermatol 2010; 35: 251-6.
43. Lebwohl MG, Medansky RS, Russo CL, et al. The comparative efficacy of sodium sulfacetamide 10%/sulfur 5% (Sulfacet-R) lotion and metronidazole 0·75% (Metrogel) in the treatment of rosacea. J Geriat Dermatol 1995; 3: 183-5.
44. Montes LF, Cordero AA, Kriner J, et al. Topical treatment of acne rosacea with benzoyl peroxide acetone gel. Cutis 1983; 32: 185-90. (Pubitemid 13037125)
45. Mostafa FF, El Harras MA, Gomaa SM, et al. Comparative study of some treatment modalities of rosacea. J Eur Acad Dermatol Venereol 2009; 23: 22-8.
46. Rigopoulos D, Kalogeromitros D, Gregoriou S, et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol 2005; 19: 564-8. (Pubitemid 41742836)
47. Sauder DN, Miller R, Gratton D, et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat 1997; 8: 79-85. (Pubitemid 27338511)
48. Torok HM, Webster G, Dunlap FE, et al. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis 2005; 75: 357-63. (Pubitemid 40905319)
49. Verea Hernando M, Margusino Framiñán L, Seco Vilariño C, et al. Comparative study of topical erythromycin and topical metronidazole in the treatment of rosacea. Farm Clin 1992; 9: 472-9.
50. Marks R, Ellis J,. Comparative effectiveness of tetracycline and ampicillin in rosacea: a controlled trial. Lancet 1971; 2: 1049-52.
51. Sneddon IB,. A clinical trial of tetracycline in rosacea. Br J Dermatol 1966; 78: 649-52.
52. Fowler JF Jr,. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol 2007; 6: 641-5.
53. Del Rosso JQ, Schlessinger J, Werschler P,. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol 2008; 7: 573-6.
54. Bamford JT, Tilden RL, Blankush JL, et al. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol 1999; 135: 659-63. (Pubitemid 29277833)
55. Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47: 284-8. (Pubitemid 351266852)
56. Pye RJ, Burton JL,. Treatment of rosacea by metronidazole. Lancet 1976; 1: 1211-12.
57. Saihan EM, Burton JL,. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol 1980; 102: 443-5. (Pubitemid 10147030)
58. Sanchez J, Somolinos AL, Almodõvar PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0·75% topical lotion in the treatment of rosacea. J Am Acad Dermatol 2005; 53: 791-7. (Pubitemid 41501364)
59. Monk BE, Logan RA, Cook J, et al. Topical metronidazole in the treatment of rosacea. J Dermatol Treat 1991; 2: 91-3.
60. Nielsen PG,. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109: 63-5. (Pubitemid 13073746)
61. Schachter D, Schachter RK, Long B, et al. Comparison of metronidazole 1% cream versus oral tetracycline in patients with rosacea. Drug Invest 1991; 3: 220-4.
62. Veien NK, Christiansen JV, Hjorth N, et al. Topical metronidazole in the treatment of rosacea. Cutis 1986; 38: 209-10. (Pubitemid 16014141)
63. Grosshans E, Michel C, Arcade B, et al. Rilmenidine in rosacea: a double blind study versus placebo. Ann Dermatol Venereol 1997; 124: 687-91. (Pubitemid 27488173)
64. Koch R, Wilbrand G,. Dark sulfonated shale oil versus placebo in the systemic treatment of rosacea. J Eur Acad Dermatol Venerol 1999; 12 (Suppl. 32): S143-4.
65. Sharquie KE, Najim RA, Al-Salman HN,. Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol 2006; 45: 857-61. (Pubitemid 43984398)
66. Wilkin JK,. Effect of nadolol on flushing reactions in rosacea. J Am Acad Dermatol 1989; 20 (2 Pt 1): 202-5. (Pubitemid 19055625)
67. Wilkin JK, De Witt S,. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol 1993; 32: 65-7. (Pubitemid 23042909)
68. Karsai S, Roos S, Raulin C,. Treatment of facial telangiectasia using a dual-wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation. Dermatol Surg 2008; 34: 702-8. (Pubitemid 351569495)
69. Neuhaus IM, Zane LT, Tope WD,. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea. Dermatol Surg 2009; 35: 920-8.
70. Thiboutot DM,. Acne and rosacea. New and emerging therapies. Dermatol Clin 2000; 18: 63-71. (Pubitemid 30013727)
71. Wilkin JK,. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994; 130: 359-62.